<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01911871</url>
  </required_header>
  <id_info>
    <org_study_id>NI10071</org_study_id>
    <secondary_id>RAF11005</secondary_id>
    <nct_id>NCT01911871</nct_id>
  </id_info>
  <brief_title>Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations</brief_title>
  <acronym>SUFEMYO</acronym>
  <official_title>Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' primary objective is to study prevalences of myocardial iron overload,
      defined as a cardiac T2*&lt; 20 ms, in 3 populations of multiply transfused patients, affected
      with thalassemia, sickle cell disease, and myelodysplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inevestigators' primary objective is to study prevalences of myocardial iron overload,
      defined as a cardiac T2*&lt; 20 ms, in 3 populations of multiply transfused patients, affected
      with thalassemia, sickle cell disease, and myelodysplasia.

      The investigators will record concomitantly parameters which, according to literature data,
      may influence the occurrence of this complication, and will look for correlations with these
      parameters and iron overload (secondary objectives), in each of the 3 cohorts.

      14 centres are involved and enrol patients with thalassemia, or sickle cell disease, or
      myelodysplasia having received in the past year &gt; 8 erythrocyte concentrates, and having had
      a cardiac MRI. Patients files register the type of the disease, age at the beginning of
      transfusion and chelation, chelator type and dosage, liver and cardiac T2*.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac T2* (MRI)</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver T2*(MRI)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Thalassemia</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Myelodysplasia</condition>
  <arm_group>
    <arm_group_label>thalassemia</arm_group_label>
    <description>patients affected with thalassemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sickle cell disease</arm_group_label>
    <description>patients affected with sickle cell disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>myelodysplasia</arm_group_label>
    <description>patients affected with myelodysplasia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>a blood sample was taken on the day of inclusion</description>
    <arm_group_label>thalassemia</arm_group_label>
    <arm_group_label>sickle cell disease</arm_group_label>
    <arm_group_label>myelodysplasia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients affected with thalassemia, SCD, and myelodysplasia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thalassemia, sickle cell disease, myelodysplasia

          -  having received in the past year &gt; 8 erythrocyte concentrates

          -  &gt; 6 years of age

        Exclusion Criteria:

          -  preexisting cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariane de montalembert, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Groupement Hospitalier Necker</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thalassemia</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>myelodysplasia</keyword>
  <keyword>transfusion</keyword>
  <keyword>chelation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

